Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (582)	6/17/1999 1:02:00 PM
From: Jim Oravetz	Respond to of 1298

Cell Genesys Gets U.S. Patent For Cancer Vaccine FOSTER CITY, Calif. -- Cell Genesys Inc. (CEGE) received a U.S. patent for its GVAX cancer vaccine. In a press release Thursday, the gene therapy developer said the vaccine, which stimulates an antitumor immune response and suppresses tumor growth, has been successful in trials on patients with prostate and lung cancer. Cell Genesys said clinical data shows the product stabilized disease in five of 17 lung cancer patients participating in the trial. The company plans to begin a multicenter clinical trial on lung cancer in the third quarter. The drug stabilized disease in 15 of 21 prostate cancer patients participating in trials. In April the company initiated a second trial for 40 patients. Nasdaq-listed shares of Cell Genesys recently traded at 4 9/16, up 1/8, or 2.8%, on volume of 22,700 shares. Average daily volume is 144,800 shares. From today WSJ (I do not follow CEGE) Good luck Jim